Either METTL14 mutation or METTL3 downregulation could reduce m6A mRNA levels and enhance proliferation of endometrial cancer cells in vitro, m6A-seq of endometrial cancer patient tumors and cell lines revealed that reduced m6A mRNA methylation could promote cell proliferation by altering the expression of key enzymes that affect the AKT signaling pathway 17. The gene discussed is METTL14; the disease is endometrial cancer.